ArticleBMC pregnancy and childbirth2025
Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Acting Injectable Antiretroviral Drugs for Pregnant and Breastfeeding Women: Current Advances, Challenges, and Future Directions.Current HIV/AIDS reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiretroviral drugs are essential for preventing mother-to-child transmission (MTCT) of HIV in HIV-infected pregnant women. However, ART treatment for HIV-infected pregnant women with multidrug resistance remains a major challenge. Effective and safe ART regimens for preventing MTCT should be tailored to this special population. Albuvirtide (ABT) is along-acting fusion inhibitor with proven efficacy and safety in adults with multidrug-resistant HIV. Herein, for the first time, we report the use of an ABT-based ART regimen in pregnant women infected with multidrug-resistant HIV. CASE PRESENTATION: A 25-year-old female HIV patient with an estimated gestational age of 14 weeks who received the TDF + 3TC + EFV regimen. The tests revealed an HIV- RNA concentration of 1730 copies/mL, a CD4 T lymphocyte (CD4 cell) concentration of 145 cells/µL and genotypic resistance to NRTI and NNRTI. The patient showed a decreased viral load (30 copies/mL) and increased CD4 cells (215 cells/µL) after 12 weeks of ABT + 3TC/DTG treatment. Her physical condition was good, and no drug- related adverse reactions occurred. By the prenatal period (40 weeks), HIV RNA became undetectable, and CD4 cells had risen to 348 cells/µL. Finally, the patient delivered a healthy female baby who was negative for HIV, and the follow-up showed normal growth.
conclusionsIn our case, ABT-based antiretroviral regimen was effective in suppressing viral load (VL) in pregnancy, and there is no reported safety issues for the mother or the baby. Albuvirtide use in pregnancy might represent a strategy to avoid in utero transmission of MDR-HIV, but further investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.